Xi Chen Lin
Net worth: 3 M $ as of 31/05/2026
Net worth: 3 M $ as of 31/05/2026
Dr. Xi Chen Lin is a Chief Scientific Officer & GM-Structure Shanghai at Structure Therapeutics, Inc. and a General Manager at Shanghai ShouTi Biotechnology Co. Ltd. Dr. Lin was previously employed as a Head-Asia Pacific External Innovation by Novo Nordisk A/S.
He received his undergraduate degree from Peking University and a doctorate degree from The Pennsylvania State University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 25/06/2026 | 228,960 ( 0.16% ) | 3 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/07/2019 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Develops biotechnologies | Chief Executive Officer | - |
| Companies | Position | End |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01/07/2019 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Peking University
Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Structure Therapeutics, Inc.
Structure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops molecule therapeutics to treat chronic diseases | Health Technology |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Develops biotechnologies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions